Skip to main content
Log in

The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer

  • Abstract
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. doi:10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  2. Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101–7. doi:10.1016/j.jhep.2012.02.016.

    Article  CAS  PubMed  Google Scholar 

  3. Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2016; doi:10.1111/crj.12605.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ali Oğul.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oğul, A., Şahin, B., Kuşçu, F. et al. The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer. J Gastrointest Canc 48, 286–287 (2017). https://doi.org/10.1007/s12029-017-9970-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9970-5

Navigation